AstraZeneca: Carcinoma, Non-Small-Cell Lung trials

The registry lists 209 Carcinoma, Non-Small-Cell Lung studies with AstraZeneca as lead sponsor. 25 are open to participants now and 63 have results posted.

Phase 1 46Phase 2 48Phase 3 44Phase 4 10No phase 71(a study in two phases counts in both)

Studies

Page 3 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Iressa 2nd Line Phase III Study in JapanCompletedNCT00252707Phase 3
• Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLCTerminatedNCT00234468Phase 3
• Iressa in the Treatment of Brain Metastases From Non Small Cell Lung CancerTerminatedNCT00234442Phase 2
• Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung CancerWithdrawnNCT00090675Phase 3
• Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung CancerCompletedNCT00081315Phase 2
• Iressa Versus Docetaxel (Taxotere)CompletedNCT00076388Phase 3
• Iressa Expanded Access Program (EAP)CompletedNCT00034879Phase 3
• ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung CancerStatus unknownNCT00006049Phase 3
• ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung CancerStatus unknownNCT00006048Phase 3